



ABN 53 075 582 740

ASX ANNOUNCEMENT
9 August 2016

Board Changes and Conclusion of Governance Review

Bionomics Limited (ASX:BNO; OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, today announced that its Chairman Mr Graeme Kaufman will retire at the end of August 2016. Bionomics also announced the conclusion of its governance review.

Bionomics' outgoing Chairman Graeme Kaufman said, "I am very pleased with the recent progress Bionomics has made in its clinical development programs and I believe the Company has a bright future. With my retirement this month I am delighted to announce the appointment of Dr Errol De Souza as Chairman. Dr De Souza has been a director of Bionomics since 2008, Chair of the Nomination Committee and chaired the recent Shareholder Working Group. I think that Errol brings a depth of commercial, scientific and governance expertise which will benefit Bionomics."

"I wish to thank the members of the Shareholder Working Group as well as our shareholders for their valued contribution and overwhelming support during the governance review process" Mr Kaufman added.

The governance review process, announced to the market on 17 February 2016, incorporated broad ranging consultations with shareholders, leading to the recent appointment of David Wilson and Peter Turner as non-executive directors.

Dr De Souza, incoming Chairman, said, "We are all extremely grateful to Graeme for his leadership over a period of significant development for Bionomics."

"While the formal process facilitated by Greenhill & Co. has been completed, Bionomics remains committed to ensuring a high level of accountability and clarity around the business strategy and performance for all shareholders, potential investors, and other stakeholders." Dr De Souza added. Bionomics' governance policies are available on its website at www.bionomics.com.au/about/corporate-governance.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Investors

Bionomics

Jack Moschakis - Company

Secretary

+61 8 8354 6181

jmoschakis@bionomics.com.au

Stern IR, Inc.

Beth Del Giacco

+1 212 362 1200

beth@sternir.com

Media

Monsoon Communications

Rudi Michelson

+61 3 9620 33

rudim@monsoon.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours;

BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.